4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
6.960 USD   -0.29%
06/244D MOLECULAR THERAPEUTICS, INC.(NASDAQGS : FDMT) dropped from Russell 2500 Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASDAQGS : FDMT) dropped from Russell 3000E Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASDAQGS : FDMT) dropped from Russell Microcap Growth Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

05/12/2022 | 04:29pm EDT

4D Molecular Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 1.22 million compared to USD 2 million a year ago. Net loss was USD 26.34 million compared to USD 16.41 million a year ago. Basic loss per share from continuing operations was USD 0.82 compared to USD 0.61 a year ago.


© S&P Capital IQ 2022
All news about 4D MOLECULAR THERAPEUTICS, INC.
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell 2500 Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell 3000E Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell Microcap Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell 3000 Growth Index
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell Small Cap Comp Growth In..
CI
06/244D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from Russell 2000 Growth Index
CI
06/22Jefferies Starts 4D Molecular Therapeutics at Buy With $22 Price Target
MT
06/214D MOLECULAR THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fisc..
AQ
06/214D MOLECULAR THERAPEUTICS, INC.(NASD : FDMT) dropped from S&P Biotechnology Select Industr..
CI
06/15TRANSCRIPT : 4D Molecular Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global ..
CI
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 4,98 M - -
Net income 2022 -100 M - -
Net cash 2022 47,1 M - -
P/E ratio 2022 -2,22x
Yield 2022 -
Capitalization 225 M 225 M -
EV / Sales 2022 35,7x
EV / Sales 2023 25,9x
Nbr of Employees 137
Free-Float 88,4%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 6,96 $
Average target price 21,20 $
Spread / Average Target 205%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Fred Kamal Chief Technical Officer
Peter Francis SVP-Clinical Translational R&D
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-68.28%225
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.09%40 503
SEAGEN INC.16.50%33 154
CELLTRION, INC.-9.34%19 151